Kuros Biosciences AG (KURN):企業の財務・戦略的SWOT分析

◆英語タイトル:Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH81908FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Kuros Biosciences AG (KURN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company’s lead sealant product is Neuroseal. The company operates in Schlieren, Switzerland; Bilthoven, the Netherlands; Burlington, USA and in Konstanz, Germany. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG Key Recent Developments

Aug 12,2020: Kuros Biosciences reports results for first half 2020
Mar 26,2020: Kuros Biosciences reports results for the full year 2019
Dec 03,2019: Kuros announces final result of Capital Increase – total gross proceeds of CHF 12.5 million raised
Aug 20,2019: Kuros Biosciences reports results for first half 2019
Jul 24,2019: Kuros announces Gerhard Ries is stepping down as Board member

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Kuros Biosciences AG – Key Facts
Kuros Biosciences AG – Key Employees
Kuros Biosciences AG – Key Employee Biographies
Kuros Biosciences AG – Major Products and Services
Kuros Biosciences AG – History
Kuros Biosciences AG – Company Statement
Kuros Biosciences AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Kuros Biosciences AG – Business Description
Geographical Segment: Other
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States of America
Performance
Kuros Biosciences AG – SWOT Analysis
SWOT Analysis – Overview
Kuros Biosciences AG – Strengths
Kuros Biosciences AG – Weaknesses
Kuros Biosciences AG – Opportunities
Kuros Biosciences AG – Threats
Kuros Biosciences AG – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Kuros Biosciences AG, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 12, 2020: Kuros Biosciences reports results for first half 2020
Mar 26, 2020: Kuros Biosciences reports results for the full year 2019
Dec 03, 2019: Kuros announces final result of Capital Increase – total gross proceeds of CHF 12.5 million raised
Aug 20, 2019: Kuros Biosciences reports results for first half 2019
Jul 24, 2019: Kuros announces Gerhard Ries is stepping down as Board member
Apr 30, 2019: Kuros Biosciences to propose re-appointment of chairman and board members at Annual General Meeting
Apr 12, 2019: Kuros Biosciences reports results for the full year 2018
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Kuros Biosciences AG, Key Facts
Kuros Biosciences AG, Key Employees
Kuros Biosciences AG, Key Employee Biographies
Kuros Biosciences AG, Major Products and Services
Kuros Biosciences AG, History
Kuros Biosciences AG, Subsidiaries
Kuros Biosciences AG, Key Competitors
Kuros Biosciences AG, Ratios based on current share price
Kuros Biosciences AG, Annual Ratios
Kuros Biosciences AG, Annual Ratios (Cont...1)
Kuros Biosciences AG, Interim Ratios
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Kuros Biosciences AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Kuros Biosciences AG (KURN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mologen AG (MGN):企業の財務・戦略的SWOT分析
    Summary Mologen AG (Mologen) is a biotechnology company that offers research and clinical development of novel drugs, immunotherapies and active ingredients. The company develops various pipeline products such as MGN1703, MGN1601, MGN1404, MGN1331 and MGN1333. It uses proprietary platform technologi …
  • Cantargia AB (CANTA):企業の財務・戦略的SWOT分析
    Summary Cantargia AB (Cantargia), a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company’s product candidate CAN04 is used for the treatment of several cancers including non-small cell lung cancer and pancreatic cancer. It …
  • Novo Nordisk AS (NOVO B)-医療機器分野:企業M&A・提携分析
    Summary Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product …
  • Hongkong Land Holdings Ltd:企業の戦略・SWOT・財務分析
    Hongkong Land Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Hongkong Land Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Inova Health System:企業の戦略的SWOT分析
    Inova Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Okamura Corporation:企業の戦略・SWOT・財務情報
    Okamura Corporation - Strategy, SWOT and Corporate Finance Report Summary Okamura Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • SMU S.A. (SMU):企業の財務・戦略的SWOT分析
    SMU S.A. (SMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Sistema JSFC:企業の戦略・SWOT・財務分析
    Sistema JSFC - Strategy, SWOT and Corporate Finance Report Summary Sistema JSFC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Oric Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Oric Pharmaceuticals Inc (Oric Pharmaceuticals) is an independent oncology company that focuses to discover and develop drugs for overcoming resistance in cancer. Its lead drug candidate ORIC-101, which is in phase 1 clinical trial, is a small molecule inhibitor of the glucocorticoid recepto …
  • Myriad Genetics Inc (MYGN):医療機器:M&Aディール及び事業提携情報
    Summary Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, personalized medicine and services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, t …
  • James Latham Plc (LTHM):企業の財務・戦略的SWOT分析
    James Latham Plc (LTHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Lonestar Resources US Inc (LONE):企業の財務・戦略的SWOT分析
    Lonestar Resources US Inc (LONE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • YGM Trading Ltd.:企業の戦略・SWOT・財務情報
    YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary YGM Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nuvo Pharmaceuticals Inc (NRI)-製薬・医療分野:企業M&A・提携分析
    Summary Nuvo Pharmaceuticals Inc (Nuvo), formerly known as Nuvo Research Inc is a drug company that offers topical pain products and technologies. The company’s product portfolio includes pennsaid, pennsaid 2%, and heated lidocaine and tetracaine patches. Its products deliver drugs topically into an …
  • China Resources Pharmaceutical Group Ltd (3320):製薬・医療:M&Aディール及び事業提携情報
    Summary China Resources Pharmaceutical Group Ltd (CR Pharma), a subsidiary of China Resources (Holdings) Co Ltd is a pharmaceutical company that offers nutritional supplements. The company offers research and development, manufacture, and distribution of whole drug products. Its products comprise ch …
  • DEA Deutsche Erdoel AG:石油・ガス:M&Aディール及び事業提携情報
    Summary DEA Deutsche Erdoel AG (DEA), a subsidiary of Letterone Holdings S.A., is an upstream company that explores for and produces oil and natural gas. The company operates onshore and offshore projects in Egyptian Nile delta, Mittelplate Island and Norwegian coast line and other regions. It also …
  • Fluidigm Corp (FLDM)-医療機器分野:企業M&A・提携分析
    Summary Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, ca …
  • PT Pertamina (Persero):企業の戦略的SWOT分析
    PT Pertamina (Persero) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Eregli Demir ve Celik Fabrikalari TAS:企業の戦略・SWOT・財務情報
    Eregli Demir ve Celik Fabrikalari TAS - Strategy, SWOT and Corporate Finance Report Summary Eregli Demir ve Celik Fabrikalari TAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Orexo AB (ORX):企業の財務・戦略的SWOT分析
    Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆